Nanobiotix is a nano medicine company developing novel therapeutics for the local treatment of cancer.

Nanobiotix provides NanoXray that offers a solution for cancer therapy based on a technology that is designed to allow destruction of cancer cells by inert particles. Its products include magnetic particles and laser activated nanoparticles for the treatment and diagnostic of cancer.

Nanobiotix was incorporated in 2003 and is based in Paris, France with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany.

The Nanobiotix philosophy is one rooted in designing pioneer physical based approaches to bring highly effective and generalized solutions to address high unmet medical needs and challenges.

Nanobiotix’s first-in-class, proprietary lead technology, NanoXray, aims to expand radiotherapy benefits for millions of cancer patients. Furthermore, Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.


Nanoiotix is backed by investors including European Investment Bank (EIB), Bpifrance, Seventure Partners, & CM CIC Capital Innovation among others. The company went public on Nov 9, 2012.



  • Year founded: 2003
  • Funding Info: $48.9M in 4 Funding Rounds (Last Funding Type: Post-IPO)
  • Yearly Revenue: $10M to $20M (2018)
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Paris
  • State: Ile-de-France
  • Country: France
Related businesses